ercutaneous transluminal angioplasty (PTA) has had a high success rate as a treatment for peripheral vascular disease, becoming an alternative to bypass surgery. [1] [2] [3] However, certain problems, such as occlusion and restenosis of the treated arteries, remain to be solved.
Intravascular stents are inserted to minimize the elastic recoil after balloon angioplasty and this additional treatment ensures immediate patency of the treated vessels for several months after the treatment. [4] [5] [6] Stents are now classified into 2 types: mechanical expansion by an angioplasty balloon (eg, Palmaz stent) or self-expanding (eg, the Wallstent).
We used a new stent made of nitinol (Symphony TM Nitinol Stent, Boston Scientific Corporation) and report our clinical experience.
Methods

Materials
The Symphony TM Nitinol Stent is a tubular prosthesis constructed from a single strand of thermal memory nickel titanium alloy filament (0.23 mm in diameter). The wire is formed into several axially arranged hexagonal cells welded together at specified locations to form an integral structure.
The stent is delivered on the tip of a catheter covered with an outer sheath to protect and constrain the stent prior to deployment (Fig 1A) . The outer diameter of the stent system is 7 French. For exact placement of the stent, there are 4 radiopaque markers on the proximal and distal ends of the outer sheath and the stent respectively. We used 2 sizes of stents: an unconstrained diameter of 8 mm and length of 44 mm, implanted in a vessel lumen of diameter 6-7 mm, and another with an unconstrained diameter of 10 mm and length of 40 mm for 7-9 mm vessels.
The delivery system has a unique shape (Fig 1B) with a double lumen structure: one is the guidewire lumen and the other is a flushing lumen, used for priming the stent capsule prior to use. The outer sheath is retracted by pulling a trigger on the proximal handle of the delivery system and as the outer sheath retracts, the stent begins to expand radially ( Fig 1C) . After removing the outer sheath completely, the stent undergoes 'shape recovery' (Fig 1D) and expands within the vessel.
Subjects
The protocol was approved by the ethics committee of National Toyohashi Higashi Hospital before the study began. Thirty-two patients (26 men, 6 women; mean age 70.6±7.8) were admitted for treatment of atherosclerosis obliterans (ASO): 19 (59%) were smokers, 11 (34%) had diabetes, 17 (53%) had hypertension, 3 (9%) had hyperlipidemia, and, 7 (22%) had ischemic heart disease. Based on their symptoms, 11 patients were classified clinically as Fontaine stage I, 16 as stage IIa, 10 as stage IIb and, 2 as stage IV. All patients underwent angiography after giving written informed consent; 39 target lesions (23 iliac artery lesions, 11 superficial femoral artery lesions, and 5 subclavian artery lesions) were treated. Based on their angiographical morphology, 26 (67%) lesions were classified as eccentric, 14 (36%) as calcified and 9 (23%) as total obstruction.
Patients were evaluated before and after the procedure and at follow-up. Quantitative angiography was performed on all lesions.
Interventional Procedures
At the beginning of the procedure, 5,000 IU of heparin was injected and then 1,000 IU each hour thereafter. The occluded segment of the artery was firstly recanalized with a guidewire and after dilation with a balloon, the stent was advanced to cover the lesion. The proximal ends of the stent and the lesion were aligned first, then the stent position was adjusted using the radiopaque markers under fluoroscopic angiographic guidance. The stent was then fully released and implanted. In all lesions, after stent delivery, additional balloon angioplasty was performed to prevent the turbulent blood flow caused by incomplete apposition of the stent struts. The average Balloon Artery ratio was 1.2±0.25, and inflation pressure was 13±5 atm.
Initial results were classified by (1) procedural success, (2) clinical success and (3) Hemodynamic success.
(1) Procedural success was defined as 30% or less residual stenosis, and/or an increase of 50% or more in luminal diameter after the procedure without major complications.
(2) Clinical success was defined by the Fontaine classification, as in maintenance of stage I, and/or improvement by at least one stage.
(3) Hemodynamic success was defined as an increase of 0.1 or more in the ankle -arm index (AAI).
For the subclavian artery lesions, we compared the bilateral brachial systolic pressure index (brachial systolic pressure on the diseased side/on the healthy side) instead of the AAI and did not evaluate the change in the Fontaine classification. Restenosis was defined as the percent diameter stenosis of more than 50% at follow-up.
Statistical Analysis
Data are presented as the mean value ± SD. Statistical significance of continuous variables was determined with a two-tailed Student t test. Categoric variables were compared by the chi-square test or Fisher exact test, when appropriate. A p value less than 0.05 was considered statistically significant.
Results
Immediate Results
We implanted 74 stents in 39 lesions during this study (35 stents in 23 iliac artery lesions; 34 stents in 11 superficial femoral artery lesions and 5 stents in 5 subclavian artery lesions).
The initial procedural success rate was 95%, and the mean percentage diameter stenosis (%DS) improved to a significant degree before and after the procedure ( Table 1) . The mean pressure gradient across the lesion also improved from 52±39 mmHg to 2±4 mmHg. Procedural failures were the result of major complications.
The initial clinical success rate was 89%; 3 patients did not improve more than one stage in the Fontaine classification, and of those patients, 2 remained at stage IV. One patient at stage IIb improved only to IIa. In all patients with subclavian artery disease, the symptoms caused by limb ischemia disappeared.
The initial hemodynamic success rate was 92%; the AAI improved from 0.50±0.4 to 0.9±0.2 (p<0.001).
Major complications occurred in 2 patients: one had a cerebral hemorrhage that was treated with conservative medical therapy and only minor paralysis remained; the other had perforation of the external iliac artery during the post dilatation of the stenting lesion because of an oversized balloon with a Balloon Artery ratio of 1.35. We successfully treated this complication with a Palmaz stent covered with an autologous vein graft.
Minor complications occurred in 3 patients: 2 suffered from distal thromboses and one developed a groin hematoma after the procedure.
Follow-up
The mean follow-up period was 6.3±1.4 months: followup angiography was performed in 33 lesions (85%; 20 iliac artery lesions, 8 superficial femoral artery lesions and 5 subclavian artery lesions) of 27 patients.
Of the 5 patients for whom follow-up angiography was not performed, one died suddenly from causes unrelated to stenting, and 3 patients were lost to follow-up because of admission to another hospital for treatment of pneumonia or cerebral infarction. The patient implanted with the Palmaz stent covered with an autologous vein graft was excluded from this study at follow-up. Angiographical findings showed that the lumen of the stent was maintained (Table 1) ; patency was 97.0% and restenosis occurred in 5 lesions (15.2%). All restenosis lesions were localized in the superficial femoral artery. There was no significant increase in the mean pressure gradient (16±3 mmHg).
Target lesion revascularization (TLR) was performed in 7 lesions (21%); in 2 of these, although the %DS was less than 50%, there was stenosis on the distal side of the stented site, which decreased distal blood flow.
The clinical success rate was 81.8% and 18 patients maintained stage I of the Fontaine classification. None of the patients with subclavian artery disease complained of symptoms.
The hemodynamic success rate was 82%; the AAI was 0.8±0.3 and there was no significant difference in the AAI immediately after the procedure.
Discussion
We used a stent made of nitinol with a new delivery system and obtained satisfactory results in patients with ASO. In a prior study by Martin at al, the initial success rate and patency rate at 6 months for a Wallstent implanted in the iliac artery were 97% and 87%, respectively. 4 Similar results were reported by Gunther at al 5, 6 and Murphy at al 7 Palmaz at al reported that the patency rate for the Palmaz stent at 8.7 months was 92%, and others have made a similar observation. [8] [9] [10] [11] [12] In the present study, the initial procedural success and patency rates (95% and 97%, respectively) are comparable with previous reports [4] [5] [6] [7] [8] [9] [10] [11] [12] and are considered equal to, or even superior to, the results obtained with the Wallstent or Palmaz stents.
Both the properties of nitinol and the new delivery system contributed to these good results. Nitinol is widely used for medical instrumentation because of its unique characteristics; [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] the rate of thrombogenicity and vascular injury is less than that with stainless steel. 23 Moreover, because of the self-expansion mechanism based on thermal memory, the expansion force of this stent is greater than that of other self-expandable stents. 19, 21, 24 The design of the new delivery system with its simple, one-handed trigger action and 4 radiopaque markers enables simple and accurate delivery.
All the restenotic lesions in the present patients were found in the distal superficial femoral artery at the 6-month follow-up and the lesions were distal to the stent. Unfavorable situations showed in Table 1 for stent implantation may have affected the restenosis rate.
We performed additional balloon dilation after insertion of the stent and although we believe that with this adjunctive balloon expansion there is a greater increase in the vessel lumen, it may not always be necessary with selfexpandable stents. One of the beneficial effects of selfexpandable stents is the reduction in vessel injury, as suggested in previous reports, and further investigation is necessary to answer the clinically important question of post-stenting balloon angioplasty.
Our results of initial treatment with Symphony Peripheral Stent TM are equal to that with other types of stents, such as the Wallstent and even the balloon-expandable Palmaz stent.
